logo
Benefit's New Foundation Is So Good, It Makes Our Skin Look Retouched

Benefit's New Foundation Is So Good, It Makes Our Skin Look Retouched

Refinery2929-07-2025
All linked products are independently selected by our editors. If you purchase any of these products, we may earn a commission.
When the weather is hot and humid, foundation is usually the first thing we ditch. Since a full face of heavy makeup can sometimes feel too much, we tend to opt for a lighter skin tint. But when we caught wind of Benefit's The POREfessional Foundation, £39.50, a new launch promising matte, pore-blurring coverage in a weightless formula, our curiosity was piqued.
If you've been doing your makeup for a while, the brand's POREfessional Face Primer has probably made its way into your rotation at some point. This OG bestseller works overtime to minimise the appearance of pores, creating a smooth canvas for makeup. This new foundation — the youngest sibling in the POREfessional family — is powered by niacinamide, a buzzy skincare ingredient that helps to refine texture, hydrate and improve skin over time.
To see if it lives up to its bold claims (and the POREfessional title), four R29 editors with different skin tones and concerns put the foundation to the test. Read ahead for our no BS reviews.
I normally love wearing skin tints in the summer, but since I have combination skin, some of my go-tos have been making my forehead and T-zone look too shiny lately — especially when I've applied sunscreen underneath. This mattifying foundation couldn't have come into my life at a better time. The star ingredient, niacinamide, helps control oil production in the skin while delivering moisture, leaving my skin with a dewy (but not overly shiny) look. The medium-buildable coverage casts a flattering yet natural glow over my face, as if it's been lightly retouched. The blackheads on my nose have all but disappeared, as have some of the discolouration and rough texture along my forehead.
But what I really can't get enough of is the texture. Benefit claims it's weightless — and I can confirm this is 100% true. I used a wet sponge to dab in the product, and it was almost strange to see my face looking brighter and more well-rested in real time when I can barely feel anything going on it, even over my normal SPF. The wear time was impressive, too. Once the foundation is applied, it clings closely to the skin's surface and barely rubs off.
My final verdict? The POREfessional Foundation has become a front-runner in my summer makeup pile, which is unusual, given it promises fuller coverage. It does a beautiful job at camouflaging all the little spots I feel self-conscious about, while making me look (and feel) like I'm not wearing much makeup at all.
L'Oréal Blackett, Unbothered editor
I've never been able to achieve the 'baddie makeup' aesthetic. Between expectations of glam bright under-eyes, carved-to-perfection contouring and a matte, filter-like finish, I've always been intimidated and gone for easy no-makeup-makeup instead. This foundation has permanently elevated my makeup game for the better. I applied a few drops on the back of my hand and went in with a sturdy brush. A little went a long way. The coverage is immediately blurring. Poof! No pores. Poof! No pigmentation marks. The smooth, airbrush-like result is so satisfying — Benefit really meant poreless. Friends and family said my skin looked 'filtered' when I had this on.
This liquid foundation dries down fast, so I recommend working quickly when blending with a wet sponge. As for the colour match, I picked medium deep shade 'Superb' (28 N). It's classed as a neutral tone, but it does show up more orange on my skin than I would prefer. It did eventually oxidise to blend in better with my skin tone, giving me a rich, deep brown warmth. Next time, I will go down one or two shades, but I am glad there's a choice between cool, warm and neutral undertones (it's a bare minimum ask for makeup brands at this point).
Jacqueline Kilikita, beauty director
I remember my friends loved Benefit's Hello Happy Soft Blur Foundation, but it was discontinued a couple of years ago. In other words, this new launch — The POREfessional Foundation — felt much needed for the brand.
Applying with a damp sponge is recommended, but I found it worked just as well with a large fluffy brush. The pigment really packs a punch. Just a pea-sized amount was enough to cover my entire face and neck, yet the finish was subtle. It's more like a tint than a full-on foundation, but it brilliantly blurs redness, post-breakout marks and dark circles. I even skipped concealer!
I usually never leave the house without powdering my T-zone — but this time, I forgot, and honestly, I didn't need it. My skin glowed in all the right places (cheekbones, brow bones) and looked fresh in areas that would normally be oily. That's thanks to additional skincare ingredient niacinamide, which supports the skin barrier and helps regulate excess oil production throughout the day. But make no mistake — it's not drying or overly matte. There's also glycerin, which keeps skin feeling quenched, while the addition of dimethicone (a smart silicone) makes skin look and feel smoother. I'm convinced that these ingredients make it last longer, too. At the end of the day, I usually need to top up in places, but my makeup looked more or less immaculate.
Karina Hoshikawa, senior writer
As an oily skin girlie, I've always loved Benefit's POREfessional range. I overwhelmingly prefer a soft matte finish with my foundation, and this one definitely fits the bill. It's on the full end of medium to full coverage and a little goes a long way; one pump was more than enough for my entire face and I didn't even use concealer with it.
I have light olive skin, and the shade 13W Champion was a perfect match. My favourite way to apply it is with a damp Beautyblender, since it is quite pigmented and the sponge helps diffuse the coverage. (On days where I want more coverage, I use a dense foundation brush.) Even before I set with powder, the foundation alone definitely has the effect of making pores and texture disappear. My lone gripe is that there was a tiny bit of oxidation, as I went on with my day, but nothing too crazy. It also lasted all day, even without priming and setting!
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Benefit's New Foundation Is So Good, It Makes Our Skin Look Retouched
Benefit's New Foundation Is So Good, It Makes Our Skin Look Retouched

Refinery29

time29-07-2025

  • Refinery29

Benefit's New Foundation Is So Good, It Makes Our Skin Look Retouched

All linked products are independently selected by our editors. If you purchase any of these products, we may earn a commission. When the weather is hot and humid, foundation is usually the first thing we ditch. Since a full face of heavy makeup can sometimes feel too much, we tend to opt for a lighter skin tint. But when we caught wind of Benefit's The POREfessional Foundation, £39.50, a new launch promising matte, pore-blurring coverage in a weightless formula, our curiosity was piqued. If you've been doing your makeup for a while, the brand's POREfessional Face Primer has probably made its way into your rotation at some point. This OG bestseller works overtime to minimise the appearance of pores, creating a smooth canvas for makeup. This new foundation — the youngest sibling in the POREfessional family — is powered by niacinamide, a buzzy skincare ingredient that helps to refine texture, hydrate and improve skin over time. To see if it lives up to its bold claims (and the POREfessional title), four R29 editors with different skin tones and concerns put the foundation to the test. Read ahead for our no BS reviews. I normally love wearing skin tints in the summer, but since I have combination skin, some of my go-tos have been making my forehead and T-zone look too shiny lately — especially when I've applied sunscreen underneath. This mattifying foundation couldn't have come into my life at a better time. The star ingredient, niacinamide, helps control oil production in the skin while delivering moisture, leaving my skin with a dewy (but not overly shiny) look. The medium-buildable coverage casts a flattering yet natural glow over my face, as if it's been lightly retouched. The blackheads on my nose have all but disappeared, as have some of the discolouration and rough texture along my forehead. But what I really can't get enough of is the texture. Benefit claims it's weightless — and I can confirm this is 100% true. I used a wet sponge to dab in the product, and it was almost strange to see my face looking brighter and more well-rested in real time when I can barely feel anything going on it, even over my normal SPF. The wear time was impressive, too. Once the foundation is applied, it clings closely to the skin's surface and barely rubs off. My final verdict? The POREfessional Foundation has become a front-runner in my summer makeup pile, which is unusual, given it promises fuller coverage. It does a beautiful job at camouflaging all the little spots I feel self-conscious about, while making me look (and feel) like I'm not wearing much makeup at all. L'Oréal Blackett, Unbothered editor I've never been able to achieve the 'baddie makeup' aesthetic. Between expectations of glam bright under-eyes, carved-to-perfection contouring and a matte, filter-like finish, I've always been intimidated and gone for easy no-makeup-makeup instead. This foundation has permanently elevated my makeup game for the better. I applied a few drops on the back of my hand and went in with a sturdy brush. A little went a long way. The coverage is immediately blurring. Poof! No pores. Poof! No pigmentation marks. The smooth, airbrush-like result is so satisfying — Benefit really meant poreless. Friends and family said my skin looked 'filtered' when I had this on. This liquid foundation dries down fast, so I recommend working quickly when blending with a wet sponge. As for the colour match, I picked medium deep shade 'Superb' (28 N). It's classed as a neutral tone, but it does show up more orange on my skin than I would prefer. It did eventually oxidise to blend in better with my skin tone, giving me a rich, deep brown warmth. Next time, I will go down one or two shades, but I am glad there's a choice between cool, warm and neutral undertones (it's a bare minimum ask for makeup brands at this point). Jacqueline Kilikita, beauty director I remember my friends loved Benefit's Hello Happy Soft Blur Foundation, but it was discontinued a couple of years ago. In other words, this new launch — The POREfessional Foundation — felt much needed for the brand. Applying with a damp sponge is recommended, but I found it worked just as well with a large fluffy brush. The pigment really packs a punch. Just a pea-sized amount was enough to cover my entire face and neck, yet the finish was subtle. It's more like a tint than a full-on foundation, but it brilliantly blurs redness, post-breakout marks and dark circles. I even skipped concealer! I usually never leave the house without powdering my T-zone — but this time, I forgot, and honestly, I didn't need it. My skin glowed in all the right places (cheekbones, brow bones) and looked fresh in areas that would normally be oily. That's thanks to additional skincare ingredient niacinamide, which supports the skin barrier and helps regulate excess oil production throughout the day. But make no mistake — it's not drying or overly matte. There's also glycerin, which keeps skin feeling quenched, while the addition of dimethicone (a smart silicone) makes skin look and feel smoother. I'm convinced that these ingredients make it last longer, too. At the end of the day, I usually need to top up in places, but my makeup looked more or less immaculate. Karina Hoshikawa, senior writer As an oily skin girlie, I've always loved Benefit's POREfessional range. I overwhelmingly prefer a soft matte finish with my foundation, and this one definitely fits the bill. It's on the full end of medium to full coverage and a little goes a long way; one pump was more than enough for my entire face and I didn't even use concealer with it. I have light olive skin, and the shade 13W Champion was a perfect match. My favourite way to apply it is with a damp Beautyblender, since it is quite pigmented and the sponge helps diffuse the coverage. (On days where I want more coverage, I use a dense foundation brush.) Even before I set with powder, the foundation alone definitely has the effect of making pores and texture disappear. My lone gripe is that there was a tiny bit of oxidation, as I went on with my day, but nothing too crazy. It also lasted all day, even without priming and setting!

Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032

Business Upturn

time23-07-2025

  • Business Upturn

Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032

New York, USA, July 23, 2025 (GLOBE NEWSWIRE) — Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea treatment market. With more women pursuing medical care for menstrual discomfort, there is a growing demand for a wide range of treatment options, including over-the-counter painkillers and hormonal therapies. Furthermore, awareness campaigns and educational initiatives are playing a key role in breaking the stigma around the condition, promoting earlier diagnosis and treatment. DelveInsight's Dysmenorrhea Treatment Market Insights report provides the current and forecast market analysis, individual leading dysmenorrhea treatment companies' market shares, challenges, dysmenorrhea treatment market drivers, barriers, trends, and key market dysmenorrhea treatment companies in the market. Key Takeaways from the Dysmenorrhea Treatment Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dysmenorrhea treatment market during the forecast period. In the treatment segment of the dysmenorrhea treatment market, the devices category accounted for the largest market share in 2024. Notable dysmenorrhea treatment companies such as Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, and several others are currently operating in the dysmenorrhea treatment market. and several others are currently operating in the dysmenorrhea treatment market. In September 2024, Organon K.K., a global healthcare company focused on women's health, announced that it had achieved the primary endpoint in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A for dysmenorrhea. Based on the trial results, the company prepared to apply for marketing approval and launch in Japan. To read more about the latest highlights related to the dysmenorrhea treatment market, get a snapshot of the key highlights entailed in the Global Dysmenorrhea Treatment Market Report Dysmenorrhea Treatment Overview Dysmenorrhea, commonly known as menstrual cramps, is managed through a combination of pharmacological and non-pharmacological treatments aimed at relieving pain and improving quality of life. First-line pharmacological therapies typically include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, which work by reducing prostaglandin production, one of the main causes of uterine contractions and pain during menstruation. For individuals who do not respond adequately to NSAIDs or have more severe symptoms, hormonal therapies like combined oral contraceptives, progestin-only pills, hormonal intrauterine devices (IUDs), or contraceptive implants may be prescribed to regulate or suppress ovulation and lessen menstrual flow, thereby reducing pain. In cases of secondary dysmenorrhea, where an underlying condition such as endometriosis or fibroids is present, treatment may be more complex and involve surgical interventions or disease-specific therapies. Non-pharmacological approaches also play an important role in dysmenorrhea management. Lifestyle modifications such as regular exercise, stress reduction, and dietary changes, like reducing caffeine and fat intake, may help alleviate symptoms. Heat therapy (using heating pads or hot baths), acupuncture, yoga, and transcutaneous electrical nerve stimulation (TENS) are complementary therapies that some individuals find beneficial. Additionally, education and counseling can empower individuals to better manage their symptoms and seek timely medical intervention when needed. As awareness about menstrual health grows, there is an increasing emphasis on personalized treatment approaches that consider the individual's medical history, symptom severity, and lifestyle preferences. Dysmenorrhea Treatment Market Insights North America dominated the dysmenorrhea treatment market in 2024, supported by several critical drivers. The region benefits from a well-established healthcare system, heightened awareness of menstrual health issues, and a growing adoption of advanced medical technologies. There has been a notable increase in the demand for non-invasive and drug-free therapies, such as TENS devices, heat therapy products, and wearable pain relief solutions. Furthermore, an increasing emphasis on women's health, favorable regulatory policies, and rising investments in R&D for innovative menstrual pain management solutions are fueling market growth. Moreover, the presence of leading companies like iPulse Medical, the manufacturer of Livia, an FDA-approved wearable device utilizing TENS to offer immediate relief from menstrual cramps, demonstrates how technological advancements and consumer demand for convenient, non-drug solutions are propelling the U.S. market. As a result, these factors are expected to significantly drive the growth of the dysmenorrhea treatment market in North America over the forecast period from 2025 to 2032. To know more about why North America is leading the market growth in the dysmenorrhea treatment market, get a snapshot of the Dysmenorrhea Treatment Market Outlook Dysmenorrhea Treatment Market Dynamics The dysmenorrhea treatment market is witnessing robust growth, driven by the rising prevalence of menstrual disorders and the increasing focus on women's health globally. Dysmenorrhea, characterized by painful menstruation, is highly prevalent among adolescent girls and women of reproductive age. This large patient base creates significant demand for effective treatment options. Over-the-counter (OTC) medications such as NSAIDs, prescription hormonal therapies like oral contraceptives, and newer non-pharmacological options such as transcutaneous electrical nerve stimulation (TENS) and dietary supplements form the current market landscape. Additionally, a growing interest in personalized and integrative approaches, including acupuncture and lifestyle modifications, is adding further diversity to the treatment landscape. Market dynamics are also shaped by increasing awareness and the gradual destigmatization of menstrual health issues. Educational campaigns, better diagnosis rates, and healthcare provider initiatives are encouraging more women to seek treatment rather than endure symptoms in silence. This positive shift in societal attitudes is contributing to a higher diagnosis rate and, consequently, expanding the market for dysmenorrhea therapies. Moreover, digital health platforms and telemedicine services are improving access to gynecological consultations, particularly in emerging markets, where access to specialized care was traditionally limited. On the competitive front, the market features a mix of established pharmaceutical companies, consumer healthcare brands, and emerging startups. While OTC NSAIDs remain the first-line therapy, the hormonal therapy segment is gaining traction due to its dual benefits of contraception and menstrual pain management. However, hormonal treatments are associated with side effects and contraindications, prompting a surge in research and development activities for novel, safer, and more targeted therapeutics. Startups and wellness brands are also tapping into consumer demand for natural and plant-based solutions, further intensifying market competition. Despite its growth potential, the dysmenorrhea treatment market faces certain challenges. Barriers such as high costs of advanced hormonal therapies, limited insurance coverage in some regions, and cultural stigmas in conservative societies can hinder treatment uptake. Furthermore, many women opt for home remedies or endure the pain without seeking medical intervention, limiting the addressable market. Ongoing clinical trials for novel non-hormonal therapies and personalized medicine approaches hold promise, but these therapies may take time to gain regulatory approvals and widespread acceptance. In summary, the dysmenorrhea treatment market is poised for steady growth, supported by a large patient base, increasing awareness, and a broadening range of treatment options. Strategic partnerships, R&D investments, and patient education will play pivotal roles in overcoming existing barriers and unlocking further growth opportunities in this market. As the focus on women's health continues to rise globally, the market is expected to see continued innovation and diversification in treatment modalities. Get a sneak peek at the dysmenorrhea treatment market dynamics @ Dysmenorrhea Treatment Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Dysmenorrhea Treatment Market CAGR ~7% Dysmenorrhea Treatment Market Size by 2032 ~USD 8 Billion Key Dysmenorrhea Treatment Companies Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, among others Dysmenorrhea Treatment Market Assessment Dysmenorrhea Treatment Market Segmentation Dysmenorrhea Treatment Market Segmentation By Type: Primary Dysmenorrhea and Secondary Dysmenorrhea Dysmenorrhea Treatment Market Segmentation By Route of Treatment: Drugs, Devices, and Others Dysmenorrhea Treatment Market Segmentation By End-User: Hospitals, Gynecology & Wellness Clinics, and Homecare Settings Dysmenorrhea Treatment Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the dysmenorrhea treatment market are set to emerge as the trendsetter explore @ Dysmenorrhea Treatment Options Table of Contents 1 Dysmenorrhea Treatment Market Report Introduction 2 Dysmenorrhea Treatment Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Dysmenorrhea Treatment Market Key Factors Analysis 6 Dysmenorrhea Treatment Market Porter's Five Forces Analysis 7 Dysmenorrhea Treatment Market Layout 8 Dysmenorrhea Treatment Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the dysmenorrhea treatment market by 2032? Click to get a snapshot of the Dysmenorrhea Treatment Market Analysis Related Reports Dysmenorrhea Market Dysmenorrhea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dysmenorrhea companies, including Daewon Pharmaceutical, PNB Vesper Life Science, Nobelpharma, among others. Dysmenorrhea Pipeline Dysmenorrhea Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dysmenorrhea companies, including Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, among others. Non-Steroidal Anti-Inflammatory Drugs Market Non-Steroidal Anti-Inflammatory Drugs Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NSAIDs companies, including Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, Sanofi, GSK plc., Heron Therapeutics, Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC., Assertio Holdings, Inc., AstraZeneca, Boehringer Ingelheim Ltd., Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, Viatris Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Eli Lilly and Company, among others. Contraceptives Market Contraceptives Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key contraceptives companies, including Teva Pharmaceutical Industries Ltd, TherapeuticsMD, Inc., AbbVie Inc., Bayer AG, The Cooper Companies Inc., FemCap Inc, Veru Inc., Meril Life Sciences Pvt. Ltd., Pregna International Limited., Reckitt Benckiser Group PLC., Viatris Inc., EUROGINE, S.L, Gedeon Richter Plc., Agile Therapeutics., Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Shanghai Dahua Pharmaceutical Co., Ltd., Pfizer Inc., Contech Devices Private Limited, Cupid Limited, among others. Menstrual Cups Market Menstrual Cups Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key menstrual cups companies, including Redcliffe Hygiene Private Limited, The Keeper, Inc., Lena Cup, INTIMINA, Blossom Cup, Mooncup Ltd, PEPTONIC Medical, YUUKI Company s.r.o., Anigan, LadyCup, Me Luna GmbH, The Flex Company, Procter & Gamble, Diva International Inc., Saalt, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program
Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program

Yahoo

time10-07-2025

  • Yahoo

Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program

Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational candidate OG-6219 in endometriosis-related pain, with OG-6219 being an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor. A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. (NYSE:OGN) acquired OG-6219 through its 2021 acquisition of Forendo Pharma. The compound did not exhibit improvement in moderate-to-severe endometriosis-related overall pelvic pain in the study as compared to the placebo, which is why Organon & Co. (NYSE:OGN) plans to discontinue the clinical development program. Juan Camilo Arjona Ferreira, M.D., Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), stated that while the study results were disappointing, the company remains committed to its focus on improving the lives of women with endometriosis. Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women's health, established brands, and biosimilars. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store